DNTH · Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Market Cap
4.729B
52 Wk Range
$35.84 - $117.88
Previous Close
$83.98
Open
$84.33
Volume
896,829
Day Range
$83.25 - $87.12
Enterprise Value
4.062B
Cash
837.8M
Avg Qtr Burn
-50.33M
Insider Ownership
0.12%
Institutional Own.
N/A
Qtr Updated
Sep 30th 2026
